Creatine on GLP-1: Does It Actually Preserve Muscle?

Creatine monohydrate is the single most-evidenced sports supplement in the literature. The International Society of Sports Nutrition (ISSN) position stand (Kreider 2017^[1]) is a 14,000-word, 313-citation review that concludes creatine monohydrate is “the most effective ergogenic nutritional supplement currently available to athletes” for increasing high-intensity exercise capacity and lean body mass during training. The follow-up ISSN consensus paper (Antonio 2021^[2]) systematically addressed the recurring safety, dosing, and population-specific questions. Two independent meta-analyses in older adults (Devries 2014^[4], Chilibeck 2017^[5]) and a third meta on ingestion strategies (Forbes 2021^[6]) converge on the same picture: 5 g/day plus resistance training preserves — and modestly grows — lean mass during caloric deficit. There are no published RCTs of creatine in GLP-1 users specifically, but the mechanism, pharmacokinetics (Persky 2003^[8]), and absence of any pharmacological interaction make the case for stacking it with semaglutide or tirzepatide as straightforward as the evidence allows.

The honest summary

• The ISSN position stand is the canonical reference. Kreider 2017^[1] reviewed several hundred trials and concluded creatine monohydrate at 3–5 g/day is safe, effective, and the most evidenced ergogenic aid available. The Antonio 2021 follow-up^[2]re-affirmed each conclusion against the post-2017 literature.
• Two meta-analyses in older adults agree. Devries 2014^[4] (357 participants across 7 RCTs) and Chilibeck 2017^[5] (405 participants across 10 RCTs) both found that creatine plus resistance training produced statistically significant gains in lean tissue mass versus resistance training alone — the population most GLP-1 patients overlap with.
• Loading is optional, not required. The standard loading protocol (20 g/day for 5–7 days) saturates muscle creatine faster, but Forbes 2021^[6] showed maintenance-only dosing (3–5 g/day) reaches the same steady-state in ~28 days with identical end-point outcomes. On a GLP-1, where GI tolerance during titration is the rate-limiting step, maintenance-only is the pragmatic default.
• GLP-1 stacking has no documented interaction. Creatine is absorbed in the small intestine with near-99% bioavailability (Persky 2003^[8]); slowed gastric emptying from semaglutide or tirzepatide does not meaningfully affect total absorption. The only practical consideration is hydration, addressed below.

What the ISSN position stand actually concludes

The 2017 ISSN position stand (Kreider et al.^[1]) is the most cited document on creatine in the sports-nutrition literature. It reviewed safety, efficacy, dosing, timing, population-specific responses, and clinical-medicine applications. The headline conclusions, verbatim from the position-stand summary statements:

• Efficacy: “Creatine monohydrate is the most effective ergogenic nutritional supplement currently available to athletes with the intent of increasing high-intensity exercise capacity and lean body mass during training.”
• Safety: “Creatine monohydrate supplementation is not only safe, but has been reported to have a number of therapeutic benefits in healthy and diseased populations ranging from infants to the elderly.”
• Dose: A loading dose of 0.3 g/kg/day (roughly 20 g for a 70 kg adult, divided into four doses) for 5–7 days, then maintenance at 3–5 g/day. Lower-dose maintenance-only protocols (3–5 g/day from day one) reach the same muscle creatine saturation in approximately 28 days.
• Form: Monohydrate is the gold standard. Other forms (creatine ethyl ester, hydrochloride, buffered, micronized claims) have not demonstrated superiority and most have weaker evidence bases.

Antonio 2021^[2] revisited each of these claims against the post-2017 literature and re-affirmed every one of them, including the safety profile in clinical populations and the absence of any documented kidney harm in people with normal renal function.

The older-adult meta-analyses: where the GLP-1 population sits

Devries 2014 (Medicine and Science in Sports and Exercise^[4]) pooled 7 RCTs of creatine plus resistance training in older adults (357 participants total) and found a statistically significant pooled effect on fat-free mass favoring the creatine arms. The effect was robust across protocols ranging from 8 to 24 weeks. Chilibeck 2017^[5] ran an updated meta on 10 RCTs in adults age 50+ and replicated the conclusion: creatine plus resistance training produces measurably more lean tissue mass and strength than resistance training alone, with a typical effect size of about 1.4 kg additional lean mass over an 8–24 week training block. Forbes 2021^[6]added a meta on ingestion strategies and reported that loading and non-loading protocols produced statistically equivalent end-of-trial outcomes when training duration was 12 weeks or longer.

This is the most relevant body of evidence for GLP-1 patients. The typical GLP-1 user is in mid-life or older, is running a meaningful caloric deficit, and is at elevated risk of disproportionate lean-mass loss because rapid weight loss from any cause — diet, surgery, or pharmacotherapy — takes roughly 25–33% of total weight as lean mass (Look 2025 SURMOUNT-1 body composition substudy^[11], Jastreboff 2022^[12]). The older-adult meta-evidence maps almost perfectly onto this clinical profile.

Loading vs maintenance: what Cooke 2014 and Forbes 2021 show

Cooke 2014 (European Journal of Applied Physiology^[3]) randomized middle-to-older-aged men to post-exercise creatine vs placebo across a structured resistance training program and found no significant timing-specific advantage to post-exercise dosing once total daily intake was matched. Antonio 2013^[7] ran the complementary pre- vs post-workout timing study in younger trained adults and likewise found small, non-statistically meaningful differences. The practical implication is that creatine timing is a low-priority variable; total daily intake hitting ~5 g is the dominant driver.

Forbes 2021^[6] compared loading-then-maintenance protocols against maintenance-only protocols at end-of-trial outcomes in older adults. Both reached the same lean-mass and strength end-points; the difference was the time to muscle saturation, not the steady-state effect. For GLP-1 patients managing nausea during dose titration, skipping loading is the pragmatic choice — four 5 g doses per day on top of a GI-active drug is a meaningful extra burden, and the end-state is identical.

Pharmacokinetics and why GLP-1 absorption changes do not matter

Persky 2003 (Journal of Clinical Pharmacology^[8]) characterized the single- and multiple-dose pharmacokinetics of oral creatine in healthy adults. Key findings:

• Bioavailability: Oral creatine is absorbed in the small intestine via the SLC6A8 creatine transporter and reaches plasma concentrations consistent with near-99% uptake at a 5 g dose.
• Plasma peak: Tmax of approximately 1–2 hours; clearance half-life of 1–2 hours.
• Muscle uptake: Skeletal muscle creatine stores accumulate over 1–4 weeks depending on dosing protocol; baseline-to-saturated represents a roughly 20–30% increase in total muscle creatine + phosphocreatine.

GLP-1 receptor agonists slow gastric emptying, which affects the timing of absorption for some co-administered drugs (the Wegovy and Zepbound FDA labels mention this in the drug-interactions sections). For creatine, the practical consequence is essentially nil: total daily uptake is what matters, not the absorption Tmax, and a 1–2 hour delay in plasma peak does not change muscle saturation over a 4-week titration. The Cooper 2012 update^[10]explicitly addressed absorption variables and concluded that co-ingestion strategies (with carbohydrate, with protein) produce small kinetic effects but do not meaningfully shift end-point outcomes.

The GLUT4 mechanism: a small but interesting bonus

Op ‘t Eijnde 2001 (Diabetes^[9]) is the canonical demonstration that oral creatine supplementation increases human skeletal-muscle GLUT4 protein content. In a controlled immobilization-and-recovery model, the creatine arm preserved GLUT4 expression while placebo lost it; during recovery, the creatine arm super-compensated GLUT4 above baseline. GLUT4 is the insulin-responsive glucose transporter in muscle and the primary determinant of insulin-stimulated glucose uptake. For GLP-1 patients — many of whom have type 2 diabetes or insulin resistance — this is a small but biologically meaningful side effect. It is not a reason to take creatine on its own; it is one more reason the risk-benefit profile is favorable.

Magnitude: lean mass retention during caloric deficit

Hydration: the one thing GLP-1 patients have to actually manage

Creatine pulls water intracellularly — typically 0.5–1.5 kg of additional total-body water in the first 1–2 weeks. On a GLP-1, where nausea, vomiting, and diarrhea during titration already raise dehydration risk and where the Wegovy Section 5.5 and Zepbound Section 5.3 labels carry explicit acute-kidney-injury warnings tied to volume depletion, the cell-water shift adds a small additional demand on hydration. The practical target is approximately 100 oz (3 liters) of fluid per day during dose escalation, a bit more if exercising in heat. This is consistent with the general fluid-intake recommendations for the GLP-1 titration period and is not a contraindication.

Cost and form: monohydrate is the gold standard

Bulk-bin creatine monohydrate runs roughly $0.10–$0.30 per 5 g serving. NSF-certified or third-party-tested products (Thorne, Klean, Optimum Nutrition Gold Standard, Bulk Supplements, Momentous) run $0.50–$1.50 per serving and are the appropriate choice for anyone competing in tested sport or wanting maximal contamination protection. Marketing claims around “micronized,” “buffered,” creatine HCl, creatine ethyl ester, and similar variants have not produced evidence of superiority over monohydrate in the meta-analyses; the ISSN position stand^[1] is explicit that monohydrate is the form with the strongest evidence base.

The practical protocol on a GLP-1

1. 5 g/day of creatine monohydrate. No loading. Reaches saturation in ~28 days with less GI burden during titration.
2. Take with a meal that includes carbohydrate, post resistance training when possible. The timing effect is small (Antonio 2013^[7], Cooke 2014^[3]) but the meal co-ingestion is well-tolerated and convenient.
3. Maintain 100 oz (3 L) fluid per day during dose escalation; a bit more if exercising in heat or at altitude.
4. Continue indefinitely. There is no benefit to cycling off; the position stand and follow-up safety reviews show no accumulation of harm with long-term use in normal-renal-function adults.
5. Pair with adequate protein and resistance training. Creatine is an amplifier, not a substitute. The primary lean-mass interventions remain protein at 1.6–2.0 g/kg/day and 2–3 resistance sessions per week.

Related research and tools

• GLP-1 muscle loss prevention protocol — the full protein + resistance training + creatine protocol with the SURMOUNT-1 DEXA evidence
• Creatine and GLP-1: lean mass, hydration, and label review — the companion article focused on the FDA-label interaction review and hydration interplay
• Exercise pairing on a GLP-1 — the resistance-training half of the protocol in depth
• Best protein powders for GLP-1 weight loss — whey, casein, plant blends, leucine content per serving
• Tirzepatide and lean mass — the SURMOUNT-1 body composition substudy in detail
• GLP-1 protein calculator — calculate your daily protein target by current weight

Important disclaimer. This article is educational and does not constitute medical advice. Patients with chronic kidney disease, reduced eGFR, or other nephrotoxic medication exposures should consult their prescriber before starting creatine. Creatine raises serum creatinine slightly, which can confound the interpretation of standard kidney-function labs. Resistance-training protocols should be individualized; patients with prior injury or significant deconditioning should work with a qualified clinician or certified strength coach. PMIDs were verified live against the PubMed E-utilities API on 2026-05-28.

Last verified: 2026-05-28. Next review: every 12 months, or sooner if new GLP-1-specific creatine RCTs are published.